<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073602</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C011</org_study_id>
    <nct_id>NCT04073602</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer</brief_title>
  <official_title>An Open-label, Single-arm, Single-center, Phase II Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in Subjects With HER2-negative Metastatic or Unresectable Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with
      locally advanced or metastatic HER2-negative urothelial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)as assessed by Investigator</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Tumor response was assessed by investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>DCR was defined as the proportion of patients who achieved an objective response or maintained stable disease during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS was defined as the time from the first study treatment to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days after the last dose of study treatment</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <description>The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).</description>
    <arm_group_label>RC48-ADC</arm_group_label>
    <other_name>Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary agreement to provide written informed consent.

          -  Male or female, Age ≥ 18 years.

          -  Predicted survival ≥ 12 weeks.

          -  Diagnosed with histologically or cytologically-confirmed locally advanced or
             metastatic urothelial cancer, originate from bladder, renal pelvis, ureter and urinary
             tract.

          -  Unresectable or disease progression (i.e. locally advanced/metastasis) after surgery
             and at least regular chemotherapy including gemcitabine, cisplatin AND paclitaxel.
             Disease progression within 6 months of the completion of neo-adjuvant and adjuvant
             chemotherapy with gemcitabine, cisplatin AND paclitaxel is also eligible.

          -  Measurable lesion according to RECIST 1.1.

          -  HER2 negative (i.e. IHC -or 1+) as confirmed by the department of Pathology in Beijing
             Cancer Hospital. Subject is able to provide specimens from primary or metastatic
             lesions for HER2 tests.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          -  Adequate organ function, evidenced by the following laboratory results within 7 days
             prior to the study treatment:

        Cardiac ejection fraction ≥ 50 %. Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥
        1.5×10^9/L Platelets ≥ 100×10^9/L; Total bilirubin ≤ 1.5× ULN; AST and ALT ≤ 2.5×ULN and ≤
        5 x ULN with hepatic metastasis; Serum creatinine ≤1.5×ULN.

          -  All female subjects will be considered to be of child-bearing potential unless they
             are postmenopausal, or have been sterilized surgically.Female subjects of
             child-bearing potential must agree to use two forms of highly effective contraception.
             Male subjects and their female partner who are of child-bearing potential must agree
             to use two forms of highly effective contraception.

          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions
             specified in this protocol.

        Exclusion Criteria:

          -  Known hypersensitivity to the components of Recombinant Humanized Anti-HER2 Monoclonal
             Antibody-MMAE Conjugate.

          -  Toxicity of previous anti-tumor treatment not recovered to CTCAE Grade 0-1 (with
             exception of Grade 2 alopecia).

          -  Pleural or abdominal effusion with clinical symptoms that requires ongoing treatment.

          -  History of receiving any anti-cancer drug/biologic treatment within 3 weeks prior to
             trial treatment.

          -  History of major surgery within 4 weeks of planned start of trial treatment.

          -  Has received a live virus vaccine within 4 weeks of planned start of trial treatment.

          -  Currently known active infection with HIV or tuberculosis.

          -  Diagnosed with HBsAg , HBcAb positive and HBV DNA copy positive, or HCVAb positive.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  History of other malignancy within the previous 3 years, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with
             a similar curative outcome as those mentioned above.

          -  known central nervous system metastases.

          -  Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD;

          -  Treated with systemic treatment (e.g. immunomodulators, corticosteroids or
             immunosuppressants) for the autoimmune disease within 2 years prior to the study
             treatment.

          -  NYHA Class III heart failure

          -  Pregnancy or lactation.

          -  Assessed by the investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Fang</last_name>
    <phone>+8610-58075763</phone>
    <email>jianminfang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

